|
|
News for Healthier Living
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
 The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval is based primarily on the results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to chemotherapy as second-line therapy for patients with metastatic pancreatic cancer, led by Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute.
August 26, 2026
September 8 2026 - Experimental Study Points to Systemic Sclerosis Treatment
- Study Identifies Stress-Response Cells, Points to New Treatment Target
- Uniformed Services University Experts Lead National Effort to Standardize Cardiac Care for Tactical Athletes
- Cognitive Behavioral Therapy May Reduce Biological Aging Among Older Adults with Insomnia
- Groundbreaking ARUP Research Clarifies Clinical Value of Atypical Cell-Free DNA Screening Results
- Different daily step count and stepping pace combos may all lower risk of early death
- When Standard Glioblastoma Therapy Is Not Enough: Second Opinion Pathways in Germany With Booking Health
- Women With Cerebral Palsy Miss Vital Gynecologic Care
- Researchers Identify New Therapeutic Target for Salt-Sensitive Hypertension
- FDA Approves New Pill For Advanced Breast Cancer Guided By Blood Test
- Laughter Could Be Great Medicine For COPD, Study Says
- A Doctor's Take: Expert-Backed Tips to Protect Kids From Germs For The School Year
- Bacteria In Classroom Dust Linked To Reduced Lung Function In Kids
- No Evidence That Sugar Substitutes Harm Weight, Health, or Sweet Taste Preferences
- Do I Have Asthma? All You Need To Know About Symptoms, Diagnosis And Treatments
- Vaccine Protects Against Multiple Fungal Infections Without Hurting the Gut
- Walking Might Be As Beneficial As Aerobics For Asthma Patients
- More Kids Using GLP-1 Drugs To Fight Obesity
- Inhaled Microplastics Linked To Lung Cancer, Study Finds
- As Probiotic Use Surges, Microbiome-Supportive Food Consumption Stagnates
- Reporter Boot Camps, In-Person Visits, and Science Comms Training Programs: A Newswise Best Practices Webinar
- Research Explores Why Strep Throat Can Linger, Even After Treatment with Antibiotics
- AI Helps Radiologists Detect 39% More Brain Aneurysm Cases in Real-World Study
- Grooming-Related Messages Reach Almost Two-Thirds of Children
September 7 2026September 5 2026September 4 2026September 3 2026September 2 2026September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026
|
|
|
|
|